Mtor Inhibitors Everolimus and Sirolimus Influence Leukocyte Migration after Ischemia.

I. Werner,A. Hernandez-Sierra,Fei Guo,Anton Moritz,Andrés Beiras-Fernández
DOI: https://doi.org/10.1097/00007890-201407151-01233
2014-01-01
Transplantation
Abstract:Background: Ischemia reperfusion injury is associated with serious inflammatory responses. Inflammation triggers mononuclear cells to migrate through vessel walls leading to irreparable tissue damage. We aimed to investigate the effect of Everolimus and Sirolimus on transendothelial migration simulating ischemia reperfusion conditions. Methods: Transendothelial migration was performed using human microvascular endothelial cells (EC) and human peripheral blood mononuclear cells (PBMC). Four different treatment groups were observed: A) control; B) activated-PBMC (PHA for 2h); C) activated-EC (IFN-γ /TNF-α for 24h); D) activated-EC and activated-PBMCs; E) both not activated. Previous to transendothelial migration, EC were placed under hypoxic conditions (<2% O2) for 2h and were further treated with Everolimus (10ng/ml Certican® Novartis, Basel, Switzerland) or Sirolimus (10ng/ml Rapamune, Pfizer, NY, USA) for 2 and 24h. Results of transmigration index (tmx) are expressed as mean ± SEM, whereas p<0.05 was considered as statistically significant. Results: The treatment with Everolimus and Sirolimus caused a significant drop of transendothelial migration in the majority of all experimental groups compared to controls. A time-dependent reduction in migrated PBMCs was evoked by Everolimus irrespectively of cell activation (both act. 2h Everolimus 0.989±0.007tmx vs. both act. 24h Everolimus 0.952±0.007tmx; EC act. 2h Everolimus 0.987±0.003tmx vs. EC act. 24h Everolimus 0.943±0.000tmx; none act 2h Everolimus 1.005±0.003tmx vs. none act. 24h Everolimus 0.971±0.005tmx). Conclusion: Sirolimus and Everolimus may prevent the pro-inflammatory migration of lymphocytes after ischemic injury. Therapy duration seems to influence the protective properties of Everolimus. DISCLOSURES:Beiras-Fernandez, A.: Speaker's Bureau, Fresenius Biotech.
What problem does this paper attempt to address?